Thrombogenics NV, of Leuven, Belgium, said results from its two-year OASIS phase IIIb study of Jetrea (ocriplasmin) were published in Ophthalmology and demonstrate the long-term efficacy and safety of the drug, a recombinant protease with activity against fibronectin and laminin, in vitreomacular adhesion (VMA).